210694-00-1

Basic information

• Product Name: 1-(neopentyloxy)-2-nitrobenzene
• Synonyms: 1-(neopentyloxy)-2-nitrobenzene;1-(2,2-Dimethylpropoxy)-2-nitrobenzene
• CAS NO: 210694-00-1
• Molecular Formula: C₁₁H₁₅NO₃
• Molecular Weight: 209.2417
• Mol File: 210694-00-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(neopentyloxy)-2-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(neopentyloxy)-2-nitrobenzene(210694-00-1)
• EPA Substance Registry System: 1-(neopentyloxy)-2-nitrobenzene(210694-00-1)

Safety Data

• Hazardous Substances Data: 210694-00-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(neopentyloxy)-2-nitrobenzene is used as a precursor for the synthesis of various organic compounds due to its unique structural features. The steric hindrance provided by the neopentyloxy group is beneficial in reactions where such effects are crucial, while the nitro group allows for a range of chemical transformations, enhancing the compound's utility in creating diverse organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(neopentyloxy)-2-nitrobenzene is utilized as a building block for the development of new drugs. Its ability to undergo various chemical reactions makes it suitable for the creation of complex molecular structures with potential therapeutic applications.
Used in Chemical Research:
1-(neopentyloxy)-2-nitrobenzene is also used in chemical research as a model compound to study the effects of steric hindrance and functional group reactivity on reaction mechanisms and outcomes, contributing to a deeper understanding of organic chemistry principles.
Used in Material Science:
In material science, 1-(neopentyloxy)-2-nitrobenzene may be employed in the development of new materials with specific properties, such as polymers with tailored characteristics,得益于其结构中的特殊官能团和空间位阻效应。
Each application takes advantage of the unique properties of 1-(neopentyloxy)-2-nitrobenzene, highlighting its importance across different fields of science and technology.

Upstream product

• 75-84-3 2,2-dimethyl-propanol-1 
• 88-75-5 2-hydroxynitrobenzene 
• 1493-27-2 ortho-nitrofluorobenzene 
• 210693-59-7 [(+/-)-BINAP]Pd(o-C₆H₄NO₂)(OCH₂CMe₃) 

Downstream Products

• 186387-94-0 [2-(2,2-dimethylpropoxy)phenyl]amine 
• 186387-00-8 1-[2-(2,2-Dimethyl-propoxy)-phenyl]-piperazine 

Relevant articles and documents

Electronic dependence of C-O reductive elimination from palladium (aryl)neopentoxide complexes

Thermal decomposition of the palladium (aryl)neopentoxide complexes [P-P]Pd(Ar)OCH2CMe3 [P-P =Tol-BINAP or BINAP; Ar p-C6H4CHO (1b), p-C6H4COPh (1c), p-C6H4NO2 (1d), o-C6H4NO2 (1e), o-C6H4CN (1F)] possessing substituents on the palladium-bound aryl group suitable for delocalization of negative charge led to quantitative (≤95%) formation of aryl ether without detectable β-hydride elimination. Thermal decomposition of 1b-f obeyed first-order kinetics, and the rate of reductive elimination decreased in the order o-NO2 > p-NO2 > p-CHO > p-COPh > o-CN. Conversely, thermal decomposition of the related derivatives [P-P]Pd(Ar)OCH2CMe3 [P-P = Tol-BINAP or BINAP; Ar p-C6H4Cl (1g), m-C6H4NO2 (1h), m-C6H4CN (1i)] which did not possess a resonance stabilizing group on the palladium-bound aryl group led to no detectable formation of aryl ether. These and related data point to the buildup of negative charge in the palladium-bound aryl group in the transition state for C-O reductive elimination and are consistent with a mechanism initiated by inner-sphere nucleophilic attack of the alkoxide ligand at the ipso-carbon atom of the palladium-bound aryl group through a zwitterionic Meisenheimer-type intermediate or transition state.

N-Arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective α1-adrenoceptor antagonists

Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype- selective antagonists by functional in vitro screening. 3-[4-(ortho- Substituted phenyl)piperazin-1:yl]propylamines were derivatized with N,N- dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4- b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a 'negative screen' for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the α(1D)-AR.